S(+) desmethylselegiline and its use in transdermal delivery compositions
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 23, 2002
Grant Date -
Nov 22, 2001
app pub date -
Mar 5, 2001
filing date -
Jan 13, 1995
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully